Printed from https://ideas.repec.org/s/spr/pharmo2.html
Content
September 2021, Volume 5, Issue 3
- 349-364 National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison
by Deepshikha Sharma & Arun Kumar Aggarwal & Laura E. Downey & Shankar Prinja - 365-383 A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
by Nan Qiao & Ralph Insinga & Gilberto de Lima Lopes Junior & John Cook & Martin Sénécal - 385-396 High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?
by Wolfgang Greiner & Keyur Patel & Christina-Jane Crossman-Barnes & Troels Vingtoft Rye-Andersen & Christian Hvid & Tom Vandebrouck - 397-410 Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology
by Graeme Ball & Mitch Levine & Lehana Thabane & Jean-Eric Tarride - 411-423 State-Level Variations and Factors Associated with Adult Vaccination Coverage: A Multilevel Modeling Approach
by Diana Garbinsky & Shannon Hunter & Elizabeth M. La & Sara Poston & Cosmina Hogea - 425-435 The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease
by Dat T. Tran & Dan Palfrey & Robert Welsh - 437-447 Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan
by Kensuke Moriwaki & Saki Uechi & Takaaki Fujiwara & Yu Hagino & Kojiro Shimozuma - 449-458 Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement
by Taryn A. G. Quinlan & Brock Schroeder & Sue Kwon & Jane F. Barlow & Michael S. Sherman & Heather D. Anderson & Garth Wright & R. Brett McQueen - 459-467 Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis
by Hansoo Kim & Greg Cook & Stephen Goodall & Danny Liew - 469-473 Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
by Yoav Golan & Yuexin Tang & Shahrul Mt-Isa & Hong Wan & Valerie Teal & Cyrus Badshah & Sanjeet Dadwal - 475-489 Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
by Deirdre B. Blissett & Joerg S. Steier & Yakubu G. Karagama & Rob S. Blissett - 491-504 Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada
by Asif Raza Khowaja & Christina Krause & Colleen Kennedy & Ben Ridout & Sarah Carriere & Craig Mitton - 505-518 Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)
by Meryl Brod & Michael Højby Rasmussen & Knud Vad & Suzanne Alolga & Donald M. Bushnell & Jacques Bedoin & Aristides Maniatis - 519-531 Economic Analysis of Transforaminal Lumbar Interbody Fusion Surgery Utilizing a Curved Bone Removal Device
by John H. Peloza & Michael A. Millgram & Erel Jacobian & Daniel E. Kolsky & Richard D. Guyer & Jean-Charles Le Huec & Ely Ashkenazi - 533-544 Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study
by Cheli Melzer Cohen & Nino Hallén & Gabriel Chodick & Lotmit Bourvine & Tal Waner & Avraham Karasik - 545-557 Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications
by Charles Ebuka Okafor - 559-559 Correction to: Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications
by Charles Ebuka Okafor
June 2021, Volume 5, Issue 2
- 139-141 Value of Information Analysis: Are We There Yet?
by Haitham Tuffaha - 143-155 Mixture Cure Models in Oncology: A Tutorial and Practical Guidance
by Federico Felizzi & Noman Paracha & Johannes Pöhlmann & Joshua Ray - 157-173 Health Economic Evidence of Point-of-Care Testing: A Systematic Review
by Deon Lingervelder & Hendrik Koffijberg & Ron Kusters & Maarten J. IJzerman - 175-186 Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma
by Neerav Monga & Jamie Garside & Matthew S. Davids & Constantine Tam & Katherine Ward & Iain Fotheringham & Peter O’Donovan & Lori Parisi & Christoph Tapprich - 187-195 Can Private Provision of Primary Care Contribute to the Spread of Antibiotic Resistance? A Study of Antibiotic Prescription in Sweden
by David Granlund & Yana V. Zykova - 197-209 Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS Perspective
by Deirdre B. Blissett & Rob S. Blissett & Matthew P. Newton Ede & Philip M. Stott & Daniel J. Cher & W. Carlton Reckling - 211-219 Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
by Bruno Detournay & Zahra Boultif & Amar Bahloul & Viviane Jeanbat & Julien Robert - 221-236 The Cost Effectiveness of Mental Health Treatment in the Lifetime of Older Adults with HIV in New York City: A Markov Approach
by Juan J. DelaCruz & Mark Brennan-Ing & Andreas Kakolyris & Omar Martinez - 237-244 An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study
by Edel Doherty & Anna Hobbins & David G. T. Whitehurst & Ciaran O’Neill - 245-250 Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe®
by T. Joseph Mattingly & Karen Li & Arnold Ng & Tieu-Long Ton-Nu & Jennifer Owens - 251-260 Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
by Ben Rothwell & Christopher Kiff & Caroline Ling & Thor-Henrik Brodtkorb - 261-273 Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market
by Sreenivasa Murthy & Pankaj Aneja & Arthur Joseph Asirvatham & Lise Lotte N. Husemoen & Nicolai A. Rhee & Jothydev Kesavadev - 275-284 Attributable Cost of Adult Hospitalized Pneumonia Beyond the Acute Phase
by Derek Weycker & Aaron Moynahan & Amanda Silvia & Reiko Sato - 285-298 Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?
by Giancarlo Pruneri & Filippo Braud & Anna Sapino & Massimo Aglietta & Andrea Vecchione & Raffaele Giusti & Caterina Marchiò & Stefania Scarpino & Anna Baggi & Giuseppe Bonetti & Jean Marie Franzini & Marco Volpe & Claudio Jommi - 299-310 Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
by Kristine Kreis & Dirk Horenkamp-Sonntag & Udo Schneider & Jan Zeidler & Gerd Glaeske & Lothar Weissbach - 311-318 The Actual Operative Costs of Liver Transplantation and Normothermic Machine Perfusion in a Canadian Setting
by Alexandria N. Webb & Dayne L. Izquierdo & Dean T. Eurich & A. M. James Shapiro & David L. Bigam - 319-329 Disparities in the Wage-and-Salary Earnings, Determinants, and Distribution of Health Economics, Outcomes Research, and Market Access Professionals: An Exploratory Study
by Ioana Popovici & Manuel J. Carvajal & Patti Peeples & Silvia E. Rabionet - 331-337 Cost of Revision Total Knee Replacement: A Protocol for Systematic Review and Meta-Analysis
by Charles Ebuka Okafor & Son Nghiem & Christopher Vertullo & Joshua Byrnes
March 2021, Volume 5, Issue 1
- 1-2 Want to Improve Public Health Access? Let’s Start with the Basics: Measuring Efficiency Correctly
by Antony Andrews - 3-11 Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
by Melissa H. Roberts & Gary T. Ferguson - 13-22 Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachel Houten & Janette Greenhalgh & James Mahon & Sarah Nevitt & Sophie Beale & Angela Boland & Tosin Lambe & Yenal Dundar & Eleanor Kotas & Joanne McEntee - 23-34 Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
by Machaon Bonafede & Rina Mehta & Gilwan Kim & Ila Sruti & Marc Tian & Corey Pelletier & Neil Goldfarb - 35-44 Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study
by Anees ur Rehman & Mohamed Azmi Ahmad Hassali & Sohail Ayaz Muhammad & Sadia Shakeel & Ong Siew Chin & Irfhan Ali Bin Hyder Ali & Jaya Muneswarao & Rabia Hussain - 45-55 Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder
by Greta Lozano-Ortega & Carol R. Schermer & David R. Walker & Shelagh M. Szabo & Basia Rogula & Alison M. Deighton & Katherine L. Gooch & Noll L. Campbell - 57-69 Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries
by Akira Yuasa & Naohiro Yonemoto & Sven Demiya & Chihiro Foellscher & Shunya Ikeda - 71-76 Costs of Respiratory Syncytial Virus Hospitalizations in Colombia
by Jefferson Antonio Buendía & Diana Guerrero Patiño - 77-88 The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
by Adam Fridhammar & Ulrika Axelsson & Ulf Persson & Anders Bjartell & Carl A. K. Borrebaeck - 89-100 Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
by Mohamed I. Elsaid & You Li & Carolyn Catalano & Carlos D. Minacapelli & Kapil Gupta & Vinod K. Rustgi - 101-109 Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study
by Fan Yang & Shan Jiang & Xiao-ning He & Hong-chao Li & Hong-yan Wu & Tian-tian Zhang & Jing Wu - 111-120 Costs and Extra Length of Stay because of Neonatal Bloodstream Infection at a Teaching Hospital in Ghana
by Ama Pokuaa Fenny & Evans Otieku & Kwaku Appiah-Korang Labi & Felix Ankomah Asante & Ulrika Enemark - 121-127 Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
by Christine M. Cramer-van der Welle & Bas J. M. Peters & Maarten J. Deenen & Franz M. N. H. Schramel & Ewoudt M. W. Garde - 129-131 Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
by Michaela R. Anderson & Peter B. Bach & Matthew R. Baldwin - 133-137 Gaining Patient Input on Naming a Novel Patient-Reported Outcome Instrument in Chronic Weight Management
by Heather Rozjabek & John Fastenau & Samara Bennett & Lydia Min-Joo Lee
December 2020, Volume 4, Issue 4
- 557-561 How Should a Safe and Effective COVID-19 Vaccine be Allocated? Health Economists Need to be Ready to Take the Baton
by Laurence S. J. Roope & John Buckell & Frauke Becker & Paolo Candio & Mara Violato & Jody L. Sindelar & Adrian Barnett & Raymond Duch & Philip M. Clarke - 563-574 Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Angela Stainthorpe & Nigel Fleeman & Rachel Houten & Marty Chaplin & Angela Boland & Sophie Beale & Yenal Dundar & Joanne McEntee & Isabel Syndikus - 575-591 Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews
by Neerav Monga & Jamie Garside & Binu Gurung & Joan Quigley & Peter O’Donovan & Christoph Tapprich & Loretta Nastoupil & Catherine Thieblemont & Christina Loefgren - 593-603 Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France
by Olivier Heinzlef & Guillaume Molinier & Benoît Hille & Lise Radoszycki & Paul Dourgnon & Juliette Longin - 605-613 Cost Analysis of the Automated Examination of Urine with the Sysmex UN-Series™ in a Spanish Population
by Óscar Herráez Carrera & María Del Monte Jarabo Bueno - 615-624 A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study
by Fernando de Andrés-Nogales & Miguel Ángel Casado & José Luis Trillo & José María Ruiz-Moreno & José Manuel Martínez-Sesmero & Gemma Peralta & José Luis Poveda & Pere Ortiz & Emilio Ignacio & Javier Zarranz-Ventura & Patricia Udaondo & Carlos Mur & Eloísa Álvarez & Enrique Cervera & Mercedes Martínez & Iñaki Llorente & Jacinto Zulueta & Mariano Rodríguez-Maqueda & Alfredo García-Layana & José Martínez-Olmos - 625-633 Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis
by Shouki Bazarbashi & Edward B. De Vol & Fatma Maraiki & Ahmed Al-Jedai & Afshan A. Ali & Ali M. Alhammad & Ibrahim A. Aljuffali & Michael Iskedjian - 635-648 Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
by Bernd Schweikert & Chiara Malmberg & Örjan Åkerborg & Gayathri Kumar & Debby Nott & Sandeep Kiri & Christophe Sapin & Susanne Hartz - 649-655 Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials
by Katherine Dick & Andrew Briggs & Henrik Brandi - 657-667 Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease
by Padraig Dixon & William Hollingworth & Jonathan Benger & James Calvert & Melanie Chalder & Anna King & Stephanie MacNeill & Katherine Morton & Emily Sanderson & Sarah Purdy - 669-677 The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
by Justin Carrico & Yang Zhao & Xiaoying Jia & Thor-Henrik Brodtkorb & Alan Mendelsohn & Simon Lowry - 679-686 A Corticosteroid-Eluting Sinus Implant Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A UK-Based Cost-Effectiveness Analysis
by Mehdi Javanbakht & Hesham Saleh & Mohsen Rezaei Hemami & Michael Branagan-Harris & Margaret Boiano - 687-696 Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population
by Joshua P. Cohen & Anne Beaubrun & Yao Ding & Rolin L. Wade & Dionne M. Hines - 697-710 Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study
by Iftekhar Khan & Mandy Maredza & Melina Dritsaki & Dipesh Mistry & Ranjit Lall & Sarah E. Lamb & Keith Couper & Simon Gates & Gavin D. Perkins & Stavros Petrou
September 2020, Volume 4, Issue 3
- 393-395 The Cost Effectiveness of Stockpiling Drugs, Vaccines and Other Health Resources for Pandemic Preparedness
by Pedro Plans-Rubió - 397-401 Economic Evaluations of Pharmacological Treatments in Heart Failure Patients: A Methodological Review with a Focus on Key Model Drivers
by Gian Luca Di Tanna & Shuxian Chen & Anna Bychenkova & Heidi S. Wirtz & Karen L. Burrows & Gary Globe - 403-418 Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
by Peter Wigfield & Urbano Sbarigia & Mahmoud Hashim & Talitha Vincken & Bart Heeg - 419-425 Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
by Brian Køster & Maria K. H. Meyer & Jes Søgaard & Peter Dalum - 427-438 Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT
by William Hollingworth & Christopher G. Fawsitt & Padraig Dixon & Larisa Duffy & Ricardo Araya & Tim J. Peters & Howard Thom & Nicky J. Welton & Nicola Wiles & Glyn Lewis - 439-447 A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use
by Sreevalsa Appukkuttan & Krishna Tangirala & Svetlana Babajanyan & Lonnie Wen & Stacey Simmons & Neal Shore - 449-458 Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
by C. Rinciog & A. Diamantopoulos & A. Gentilini & B. Bondue & C. Dahlqvist & A. Froidure & W. A. Wuyts & S. Soulard - 459-472 DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost–Utility Analysis
by Mehdi Javanbakht & Mohsen Rezaei Hemami & Atefeh Mashayekhi & Michael Branagan-Harris & Azfar Zaman & Yahya Al-Najjar & Donal O’Donoghue & Farzin Fath-Ordoubadi & Stephen Wheatcroft - 473-483 Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
by Robert M. Rifkin & Jill A. Bell & Pronabesh DasMahapatra & Michael Hoole & Maria Lowe & Chris Curran & Scott Campbell & Peijie Hou & Dorothy Romanus - 485-497 Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
by Itziar Oyagüez & Carmen Suárez & José Luis López-Sendón & José Ramón González-Juanatey & Fernando Andrés-Nogales & Jorge Suárez & Carlos Polanco & Javier Soto - 499-510 Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in Pregnancy
by Cate Bailey & Helen Skouteris & Cheryce L. Harrison & Jacqueline Boyle & Rebeccah Bartlett & Briony Hill & Shakila Thangaratinam & Helena Teede & Zanfina Ademi - 511-517 Self-Monitoring and Management of Blood Pressure in Patients with Stroke or TIA: An Economic Evaluation of TEST-BP, A Randomised Controlled Trial
by Lois G. Kim & Edward C. F. Wilson & William J. Davison & Allan B. Clark & Phyo K. Myint & John F. Potter - 519-528 Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US
by Steve Edelman & Fang Liz Zhou & Ronald Preblick & Sumit Verma & Sachin Paranjape & Michael J. Davies & Vijay N. Joish - 529-539 HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
by Mikyung Kelly Seo & Oddbjørn Straume & Lars A. Akslen & John Cairns - 541-547 Metabolic Acidosis in Preterm Infants is Associated with a Longer Length of Stay in the Neonatal Intensive Care Unit
by Marika Paul & Jamie Partridge & Bridget Barrett-Reis & Kaashif A. Ahmad & Pattabhi Machiraju & Hemalatha Jayapalan & Richard J. Schanler - 549-550 Comment on: “Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights”
by Omar Salamanca - 551-552 Authors’ Reply to Salamanca: “Systematic Review of Economic Evaluations in Primary Open Angle Glaucoma: Decision Analytic Modeling Insights”
by Jose Bartelt-Hofer & Steffen Flessa - 553-554 Correction to: Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
by Brian Køster & Maria K. H. Meyer & Jes Søgaard & Peter Dalum
June 2020, Volume 4, Issue 2
- 203-205 Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic
by Anthony J. Hatswell - 207-210 Group Testing for SARS-CoV-2: Forward to the Past?
by Koen B. Pouwels & Laurence S. J. Roope & Adrian Barnett & David J. Hunter & Terry M. Nolan & Philip M. Clarke - 211-222 A Systematic Review of Model-Based Economic Evaluations of Treatments for Venous Leg Ulcers
by Ashley Layer & Emma McManus & N. J. Levell - 223-233 Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review
by T. I. Armina Padmasawitri & Sarah Maria Saragih & Gerardus W. Frederix & Olaf Klungel & Anke M. Hövels - 235-247 Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
by Herbert H. Loong & Carlos K. H. Wong & Linda Kam Suet Leung & Praveen Dhankhar & Ralph P. Insinga & Sheenu Chandwani & Danny C. Hsu & Mary Y. K. Lee & Min Huang & James Pellissier & Akanksha Rai & Monika Achra & Seng Chuen Tan - 249-261 Cost of Delivering Secondary Healthcare Through the Public Sector in India
by Shankar Prinja & Akashdeep Singh Chauhan & Pankaj Bahuguna & Sakhtivel Selvaraj & V. R. Muraleedharan & Thiagarajan Sundararaman - 263-276 Touch for Health: Use of Pavlovian Processes with Physical Touch as a Means to Improve Menstrual Hygiene Management Initiatives, Measured by Willingness to Pay
by Siobhan K. Yilmaz & Alok K. Bohara & Soumi Roy Chowdhury - 277-286 Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
by Margarita Capel & Andreea Ciudin & María Mareque & Raquel María Rodríguez-Rincón & Susana Simón & Itziar Oyagüez - 287-296 Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines
by Emma Connolly & Helen O’Donnell & Felicity Lamrock & Lesley Tilson & Michael Barry - 297-305 Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts
by D. Coyle & Pierre J. A. Villeneuve - 307-319 Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis
by Mehdi Javanbakht & Miranda Trevor & Mohsen Rezaei Hemami & Kazem Rahimi & Michael Branagan-Harris & Fabian Degener & Daniel Adam & Franziska Preissing & Jörg Scheier & Suzanne F. Cook & Eric Mortensen - 321-330 Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands
by Judith J. Gout-Zwart & Lisa A. Jong & Lisanne Saptenno & Maarten J. Postma - 331-342 Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India
by Suhaj Abdulsalim & Mazhuvancherry Kesavan Unnikrishnan & Mohan K. Manu & Saud Alsahali & Alian A. Alrasheedy & Antony P. Martin & Brian Godman & Abubakr A. Alfadl - 343-351 Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
by Rachael Batteson & Rose Hart & Matthew Hemstock & Kyna Gooden & Srividya Kotapati & Stephane Roze & Dawn Lee & Adenike Amadi - 353-359 The Costs of Industry-Sponsored Drug Trials in Canada
by Dat T. Tran & Ilke Akpinar & Philip Jacobs - 361-380 A Nationwide Study of Prevalence Rates and Characteristics of 199 Chronic Conditions in Denmark
by Michael Falk Hvidberg & Soeren Paaske Johnsen & Michael Davidsen & Lars Ehlers - 381-388 Treatment Patterns and Costs Associated with Stage IV Non-Small Cell Lung Cancer in a Mexican Population: A Chart Review
by Jorge Arturo Alatorre & Saúl Campos-Gómez & Emmanuel De la Mora & Diego Novick & Angélica Cruz & Jimena María Iglesias-Chiesa - 389-392 Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program
by Christine Leopold & Carina Araujo-Lane & Carol Rosenberg & Melissa Gilkey & Anita K. Wagner
March 2020, Volume 4, Issue 1
- 1-4 Registered Reports: Time to Radically Rethink Peer Review in Health Economics
by Philip Clarke & John Buckell & Adrian Barnett - 5-12 Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
by Jose Bartelt-Hofer & Lilia Ben-Debba & Steffen Flessa - 13-25 Health State Utility Data in Cystic Fibrosis: A Systematic Review
by Bishal Mohindru & David Turner & Tracey Sach & Diana Bilton & Siobhan Carr & Olga Archangelidi & Arjun Bhadhuri & Jennifer A. Whitty - 27-36 The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada
by Cody D. Black & Kednapa Thavorn & Doug Coyle & Lise M. Bjerre - 37-44 The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model
by Zhuo T. Su & Jose Bartelt-Hofer & Stephen Brown & Elisheva Lew & Luc Sauriol & Lieven Annemans & Daniel T. Grima - 45-60 Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa
by S. Boyer & M. L. Nishimwe & L. Sagaon-Teyssier & L. March & S. Koulla-Shiro & M.-Q. Bousmah & R. Toby & M. P. Mpoudi-Etame & N. F. Ngom Gueye & A. Sawadogo & C. Kouanfack & L. Ciaffi & B. Spire & E. Delaporte - 61-69 An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals
by Panos Panagiotopoulos & Nikos Maniadakis & George Papatheodoridis & Dimitris Pektasidis - 71-77 Return on Investment of Free Colorectal Cancer Screening Tests in a Primarily Rural Uninsured or Underinsured Population in Northeast Texas
by Gabriela Orsak & Anastasia Miller & Carlton M. Allen & Karan P. Singh & Paul McGaha - 79-90 Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
by Hélène Parise & Robert Espinosa & Katherine Dea & Pablo Anaya & Giovanny Montoya & Daniel Bin Ng - 91-103 Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden
by Korinna Karampampa & Hanna Gyllensten & Fei Yang & Chantelle Murley & Emilie Friberg & Jan Hillert & Kristina Alexanderson - 105-117 Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis
by Natalie Boytsov & Xiang Zhang & Kristin A. Evans & Barbara H. Johnson - 119-131 US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
by Dominic Pilon & Holly Szukis & Kruti Joshi & David Singer & John J. Sheehan & Jennifer W. Wu & Patrick Lefebvre & Paul Greenberg - 133-142 Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
by Ash Bullement & Samuel Thomas McMordie & Anthony James Hatswell & Nanxin Li & Koo Wilson - 143-157 Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana
by Samuel N. Frempong & Andrew J. Sutton & Clare Davenport & Pelham Barton - 159-169 A Cost-Effectiveness Analysis Comparing the VivaSight Double-Lumen Tube and a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation
by Sara Larsen & Jimmy Højberg Holm & Tove Nørgaard Sauer & Claus Andersen - 171-179 Buccal Midazolam Solution for the Management of Prolonged Acute Convulsive Seizures: A Cost Analysis
by Catherine Ludwig & Lauri Fisher - 181-190 Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis
by Paola Rucci & Vera Maria Avaldi & Claudio Travaglini & Cristina Ugolini & Elena Berti & Maria Luisa Moro & Maria Pia Fantini - 191-201 Symptoms and Dietary Impact in Hypertriglyceridemia-Associated Pancreatitis: Development and Content Validity of Two New Measures
by Claire Burbridge & Jason A. Randall & Robert J. Sanchez & Hayes Dansky & Tara Symonds & Cynthia J. Girman & Joshua A. Strayer & Karen L. Selk & David C. Whitcomb & Erin E. Kershaw
December 2019, Volume 3, Issue 4
- 433-435 Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations
by Geert W. J. Frederix - 437-451 A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers
by Naghmeh Foroutan & Jean-Eric Tarride & Feng Xie & Fergal Mills & Mitchell Levine - 453-461 Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & James Mahon & Sarah Nevitt & Rui Duarte & Angela Boland & Eleanor Kotas & Yenal Dundar & Joanne McEntee & Sajjad Ahmad - 463-478 Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review
by Pablo E. Pergola & Roberto Pecoits-Filho & Wolfgang C. Winkelmayer & Bruce Spinowitz & Samuel Rochette & Philippe Thompson-Leduc & Patrick Lefebvre & Gigi Shafai & Ana Bozas & Myrlene Sanon & Holly B. Krasa - 479-493 A Systematic Review of the Health Economics of Pompe Disease
by Benedikt Schoser & Andreas Hahn & Emma James & Digant Gupta & Matthew Gitlin & Suyash Prasad - 495-504 Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial
by Laura Pirhonen & Kristian Bolin & Elisabeth Hansson Olofsson & Andreas Fors & Inger Ekman & Karl Swedberg & Hanna Gyllensten - 505-515 Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)
by Osvaldo Ulises Garay & Marie Libérée Nishimwe & Marwân-al-Qays Bousmah & Asmaa Janah & Pierre-Marie Girard & Geneviève Chêne & Laetitia Moinot & Luis Sagaon-Teyssier & Jean-Luc Meynard & Bruno Spire & Sylvie Boyer - 517-526 National Health Insurance Databases in Indonesia, Vietnam and the Philippines
by Junice Yi Siu Ng & Royasia Viki Ramadani & Donni Hendrawan & Duong Tuan Duc & Pham Huy Tuan Kiet - 527-535 Use of Initial Noninvasive Cardiac Testing and Association with Downstream Healthcare Resource: A Retrospective Review of Resources Used Across a 12-Month Window for Probable Type I Myocardial Infarction Patients
by Dana Villines & Wm. Thomas Summerfelt & James R. Spalding & Therese M. Kitt & Rita M. Kristy & Christy R. Houle - 537-550 Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
by Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter - 551-558 Using Time Trade-Off Methods to Elicit Short-Term Utilities Associated with Treatments for Bulbar Urethral Stricture
by Jing Shen & Matthew Breckons & Luke Vale & Robert Pickard - 559-570 Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
by Claire Telford & Evelina Bertranou & Samuel Large & Hilary Phelps & Mattias Ekman & Christopher Livings - 571-581 Using a Discrete-Choice Experiment to Estimate the Preferences of Clinical Practitioners for a Novel Non-invasive Device for Diagnosis of Peripheral Arterial Disease in Primary Care
by Yemi Oluboyede & Laura Ternent & Luke Vale & John Allen - 583-589 Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017
by Cara Usher & Laura McCullagh & Lesley Tilson & Michael Barry - 591-597 The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta
by Ilke Akpinar & Arto Ohinmaa & Lars Thording & Dat T. Tran & Richard N. Fedorak & Lawrence Richer & Philip Jacobs - 599-618 Long-Term Inpatient Hospital Utilisation and Costs (2007–2008 to 2015–2016) for Publicly Waitlisted Bariatric Surgery Patients in an Australian Public Hospital System Based on Australia’s Activity-Based Funding Model
by Julie A. Campbell & Martin Hensher & Daniel Davies & Matthew Green & Barry Hagan & Ian Jordan & Alison Venn & Alexandr Kuzminov & Amanda Neil & Stephen Wilkinson & Andrew J. Palmer - 619-629 Smart Pump–Electronic Health Record (EHR) Interoperability with Auto-Documentation is Associated with Increased Submission of Infusion-Therapy Billing Claims at a Community Hospital
by Tina M. Suess & John W. Beard & Michael Ripchinski & Matthew Eberts & Kevin Patrick & Leo J. P. Tharappel - 631-641 A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa
by Letlhogonolo Makhele & Moliehi Matlala & Mncengeli Sibanda & Antony P. Martin & Brian Godman - 643-645 Indonesian Social Health Insurance Sample Data are Now Available and Accessible for Research
by Anis Fuad - 647-647 Correction to: A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa
by Letlhogonolo Makhele & Moliehi Matlala & Mncengeli Sibanda & Antony P. Martin & Brian Godman
September 2019, Volume 3, Issue 3
- 279-280 Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness
by Erik Landfeldt - 281-291 Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK
by Yaling Yang & Lucy Abel & James Buchanan & Thomas Fanshawe & Bethany Shinkins - 293-302 Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & Adrian Bagust & Rui Duarte & Marty Richardson & Sarah Nevitt & Angela Boland & Eleanor Kotas & Joanne McEntee & Nicky Thorp - 303-309 Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
by Sabine Vogler & Peter Schneider & Nina Zimmermann - 311-319 The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method
by Najme Moradi & Arash Rashidian & Shirin Nosratnejad & Alireza Olyaeemanesh & Marzieh Zanganeh & Leila Zarei - 321-331 Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
by Peter L. Quon & Ying Xiao & Sonja Sorensen & Amir Abbas Tahami Monfared - 333-342 Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
by Luis Manuel Entrenas Costa & Francisco Casas-Maldonado & José Gregorio Soto Campos & Alicia Padilla-Galo & Alberto Levy & Francisco Javier Álvarez Gutiérrez & Ana P. Gómez-Bastero Fernández & Concepción Morales-García & Rocío Gallego Domínguez & Gustavo Villegas Sánchez & Luis Mateos Caballero & Antonio Pereira-Vega & Cayo García Polo & Gerardo Pérez Chica & Juan José Martín Villasclaras - 343-350 Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group
by Stuart Keeping & Paul N. Deslandes & Kathryn E. Haines & Philip A. Routledge - 351-358 The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
by Dawn Lee & Nic Brereton & Sujith Dhanasiri & Austin Kulasekararaj - 359-365 Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
by Shaji Sebastian & Jenna Roberts & John Waller & Davneet Judge & Chloe Brown & Ruth Davies & Sumesh Kachroo - 367-375 Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
by Kristen L. McCausland & Avery A. Rizio & Michelle K. White & Martha S. Bayliss & Tiffany P. Quock - 377-390 Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
by Ash Bullement & Paul Nathan & Anna Willis & Amerah Amin & Cameron Lilley & Ceilidh Stapelkamp & Anthony Hatswell & Chris Pescott & Murtuza Bharmal - 391-402 Cost of Treatment of Valvular Heart Disease at a Tertiary Hospital in North India: Policy Implications
by Shankar Prinja & Yashpaul Sharma & Jyoti Dixit & Shyam Kumar Singh Thingnam & Rajesh Kumar - 403-410 A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
by M. J. Walton & J. O’Connor & C. Carroll & L. Claxton & R. Hodgson - 411-417 Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials
by Joshua K. Porter & Gian Luca Di Tanna & Richard B. Lipton & Sandhya Sapra & Guillermo Villa - 419-422 All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe
by Jacoline C. Bouvy & Michelle Mujoomdar - 423-426 All Male Panels and Other Diversity Considerations for ISPOR
by Nancy J. Devlin - 427-427 Correction to: Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations
by Jing Shen & Sarah Hill & David Mott & Matthew Breckons & Luke Vale & Rob Pickard
June 2019, Volume 3, Issue 2
- 129-132 Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research
by James Buchanan & Sarah Wordsworth - 133-141 Working with Patients and Members of the Public: Informing Health Economics in Child Health Research
by Rebecca Kandiyali & Annie Hawton & Christie Cabral & Julie Mytton & Valerie Shilling & Christopher Morris & Jenny Ingram - 143-150 Measuring the Benefits of Decision Aids for Economic Evaluation
by Thomas Butt - 151-161 Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation
by Emily South & Edward Cox & Nick Meader & Nerys Woolacott & Susan Griffin - 163-176 Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis
by Karen Pickering & Ioannis D. Gallos & Helen Williams & Malcolm J. Price & Abi Merriel & David Lissauer & Aurelio Tobias & G. Justus Hofmeyr & Arri Coomarasamy & Tracy E. Roberts - 177-188 Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
by Bruno Emond & Kruti Joshi & Antoine C. El Khoury & Marie-Hélène Lafeuille & Dominic Pilon & Neeta Tandon & Hela Romdhani & Patrick Lefebvre - 189-195 Cost Comparison of Single-Use Versus Reusable Bronchoscopes Used for Percutaneous Dilatational Tracheostomy
by Anne Sohrt & Lars Ehlers & Flemming Witt Udsen & Anders Mærkedahl & Brendan A. McGrath - 197-204 The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities
by Markian Pahuta & Aaron Frombach & Emile Hashem & Stewart Spence & Christina Sun & Eugene K. Wai & Joel Werier & Carl Walraven & Doug Coyle - 205-213 High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): Retrospective Analysis of the Kids’ Inpatient Database (KID)
by Jessica Cardenas & Melissa Menier & Marjet D. Heitzer & Douglas M. Sproule - 215-227 Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial
by Iftekhar Khan & Stavros Petrou & Kamran Khan & Dipesh Mistry & Ranjit Lall & Bart Sheehan & Sarah Lamb - 229-235 Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain
by Blanca Boluda & Rebeca Rodríguez-Veiga & David Martínez-Cuadrón & Ignacio Lorenzo & Jaime Sanz & Ana Regadera & Amparo Sempere & Leonor Senent & Jose Vicente Cervera & Pilar Solves & John Reitan & Salvador Gea & Miguel Angel Sanz & Pau Montesinos - 237-245 Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
by Jill A. Bell & Aaron Galaznik & Marlo Blazer & Huai-Che Shih & Eileen Farrelly & Augustina Ogbonnaya & Michael Eaddy & Robert J. Fram & Douglas V. Faller - 247-254 Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
by Lara Benigno Porto & Ivan Ricardo Zimmermann & Luciana Ansaneli Naves - 255-264 Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan
by Timothy Bolt & Hisanori Kobayashi & Jörg Mahlich - 265-272 Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes
by Anne Sohrt & Anders Mærkedahl & William V. Padula - 273-273 Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes
by Anne Sohrt & Anders Mærkedahl & William V. Padula - 275-275 Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes
by Anne Sohrt & Anders Mærkedahl & William V. Padula - 277-277 Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
by James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker
March 2019, Volume 3, Issue 1
- 1-3 Value Assessment Frameworks in the United States: A Call for Patient Engagement
by Vakaramoko Diaby & Askal A. Ali & Alberto J. Montero - 5-20 Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations
by Jing Shen & Sarah Hill & David Mott & Matthew Breckons & Luke Vale & Rob Pickard - 21-30 Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease
by Eoin Moloney & Joanne O’Connor & Dawn Craig & Shannon Robalino & Alexandros Chrysos & Mehdi Javanbakht & Andrew Sims & Gerard Stansby & Scott Wilkes & John Allen - 31-42 Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil
by Denise Razzouk - 43-54 Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
by D. Lee & A. Amadi & J. Sabater & J. Ellis & H. Johnson & S. Kotapati & S. McNamara & A. Walker & M. Cooper & K. Patterson & N. Roskell & Y. Meng - 55-69 Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0–9 Years with Pertussis in Catalonia (Spain)
by Pedro Plans-Rubió & Encarna Navas & Pere Godoy & Gloria Carmona & Angela Domínguez & Mireia Jané & Carmen Muñoz-Almagro & Pedro Brotons - 71-80 Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
by Meryl Brod & Jane F. Beck & Lise Højbjerre & Donald M. Bushnell & Johan Erpur Adalsteinsson & Lars Wilkinson & Michael Højby Rasmussen - 81-91 Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
by Alex Diamantopoulos & Toby M. Maher & Nils Schoof & Dirk Esser & Corinne LeReun - 93-102 Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective
by Koji Makino & Dominic Tilden & Carmel Guarnieri & Mia Mudge & Ian J. Baguley - 103-117 International HTA Experience with Targeted Therapy Approvals for Lung Cancer
by Fatma Maraiki & J. Byrnes & H. Tuffaha & M. Hinder - 119-126 Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation
by Steven P. Kennedy & Hanna Iaizzo & Evgueni Fayn & Dalip Singh - 127-127 Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
by D. Lee & A. Amadi & J. Sabater & J. Ellis & H. Johnson & S. Kotapati & S. McNamara & A. Walker & M. Cooper & K. Patterson & N. Roskell & Y. Meng
December 2018, Volume 2, Issue 4
- 357-358 Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary
by Erik Nord & Christoffer Lamøy - 359-369 Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
by Hong Xiao & Xinyi Jiang & Cheng Chen & Alberto J. Montero & Vakaramoko Diaby - 371-380 Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events
by Laurence M. Djatche & Stefan Varga & Robert D. Lieberthal - 381-392 Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy Controls
by Caroline C. Kingdon & Erinna W. Bowman & Hayley Curran & Luis Nacul & Eliana M. Lacerda - 393-402 Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
by David Nathanson & Ugne Sabale & Jan W. Eriksson & Thomas Nyström & Anna Norhammar & Urban Olsson & Johan Bodegård - 403-413 Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease
by James Lomas & Miqdad Asaria & Laura Bojke & Chris P. Gale & Gerry Richardson & Simon Walker - 415-421 Out-of-Pocket Household Expenditures on Medical Injections in Cambodia
by Sachiko Ozawa & Tatenda T. Yemeke & Alie F. Tawah & Vivek Kulkarni & Manuela Villar Uribe - 423-432 Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications
by Arianit Jakupi & Brian Godman & Antony Martin & Alan Haycox & Indrit Baholli - 433-442 The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada
by Dat T. Tran & Arto Ohinmaa & Nguyen X. Thanh & Robert C. Welsh & Padma Kaul - 443-458 An Exploratory Study: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D for Long-Term Publicly Waitlisted Bariatric Surgery Patients Before and 3 Months After Bariatric Surgery
by Julie A. Campbell & Martin Hensher & Amanda Neil & Alison Venn & Petr Otahal & Stephen Wilkinson & Andrew J. Palmer - 459-467 The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study
by Claudio Jommi & Patrizio Armeni & Margherita Battista & Paolo Procolo & Giuseppe Conte & Claudio Ronco & Mario Cozzolino & Anna Maria Costanzo & Umberto Luzio Paparatti & Gabriella Concas & Giuseppe Remuzzi
September 2018, Volume 2, Issue 3
- 221-224 Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?
by Livio Garattini & Anna Padula